Antiverse

Antiverse, a UK-based biotech company, has closed a Series A funding round of £7 million led by Soulmates Ventures, with participation from other investors including Innovation Investment Capital, DOMiNO Ventures, and existing investors.

Summary of transaction details:

• Value: £7 million
• Sector: Healthcare & Biotech
• Advisor: Not disclosed
• Key Entities: Antiverse, Soulmates Ventures, Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital, i&i Biotech Fund
• Location: United Kingdom

Note: This investment underscores the growing interest in biotech companies that utilize AI for therapeutic antibody development, highlighting the potential for such technologies to address previously undruggable disease targets.